Colorectal Cancer | Specialty

The OncLive Colorectal Cancer condition center page is a comprehensive resource for clinical news and expert insights on colorectal cancer treatment and management, with a focus on novel therapeutic strategies including checkpoint inhibitors and TKIs across lines of therapy. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in colorectal cancer.

Dr. Schmoll on the Objective of CHARTA for CRC

August 10th 2017

Hans-Joachim Schmoll, MD, head, Department of Oncology and Hematology, associate professor, Internal Medicine, Hematology/ Oncology, University Hospital Halle, discusses the objective of the CHARTA study for patients with colorectal cancer (CRC).

Dr. Diaz on Response Rates With Pembrolizumab for CRC

August 3rd 2017

Luis A. Diaz, MD, head of the division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, discusses the response rates of pembrolizumab (Keytruda) for patients with colorectal cancer (CRC).

Biomarker Basics: A Look at MSI's Growing Role

August 2nd 2017

The recent approval of 2 immunotherapies for the treatment of certain patients with tumors that exhibit microsatellite instability has propelled the emerging biomarker into clinical practice, prompting calls for broader genetic testing.

FDA Approves Nivolumab for MSI-H or dMMR Colorectal Cancer

August 1st 2017

The FDA has granted an accelerated approval to nivolumab for the treatment of adult and pediatric patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.

HER2 Status in Colorectal Cancer

July 13th 2017

Evidence in BRAF-Mutant CRC Tumors

July 13th 2017

CRC: Emerging Immunotherapy Strategies in MSS Tumors

July 13th 2017

Pembrolizumab in MSI-H CRC Tumors

July 13th 2017

Role of Trifluridine/Tipiracil in CRC

July 13th 2017

Patient Selection for Regorafenib in CRC

July 13th 2017

Sequencing Considerations in MSS CRC Tumors

July 13th 2017

Exploring Second-Line Therapeutic Options in mCRC

July 13th 2017

Global Perspectives and Initial Decisions in mCRC

July 13th 2017

IDEA Trial: 3 vs 6 Months of Adjuvant Therapy in CRC

July 13th 2017

Exploring Global Variations in Molecular Profiling

July 13th 2017

Maintenance and Second-Line Decisions in mCRC

July 13th 2017

Frontline Decisions in RAS Wild-Type Left-Sided mCRC

July 13th 2017

Nuances in Antibody Selection: Left Vs Right-Sided mCRC

July 13th 2017

Prognostic/Predictive Value of Tumor-Sidedness in CRC

July 13th 2017

Colorectal Cancer Prevention and Screening: An Update

July 13th 2017